Evidence map›Paper›PMID 42851992›Full record

ArticleACS omega2026

The PTPN1/N2 Peptide Inhibitor Achieves Potent, Long-Acting Glycemic Control and Weight-Loss Dual Efficacy in Mice.

Yiying Shi, Xianmin Yang, Fanxu Meng, Anton Feenstra, Jin Chen, Zongwen Gu, Xiang Gao, Wenqing Yao, Guozhen Dong, Liyan Gong and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yiying ShiQingdao Key Laboratory of Biomacromolecular Drug Discovery and Development, College of Chemical Engineering, Qingdao University of Science and Technology, Qingdao 266042, China.
Xianmin YangQingdao Key Laboratory of Biomacromolecular Drug Discovery and Development, College of Chemical Engineering, Qingdao University of Science and Technology, Qingdao 266042, China.
Fanxu MengDepartment of Computer Science, Vrije Universiteit Amsterdam, 1081HV Amsterdam, The Netherlands.
Anton FeenstraDepartment of Computer Science, Vrije Universiteit Amsterdam, 1081HV Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0001-6755-9667
Jin ChenQingdao Center of Technology Innovation for Shark Antibody Development, College of Biological Engineering, Qingdao University of Science and Technology, Qingdao 266042, China.
Zongwen GuQingdao Key Laboratory of Biomacromolecular Drug Discovery and Development, College of Chemical Engineering, Qingdao University of Science and Technology, Qingdao 266042, China.
Xiang GaoQingdao Key Laboratory of Biomacromolecular Drug Discovery and Development, College of Chemical Engineering, Qingdao University of Science and Technology, Qingdao 266042, China.
Wenqing YaoQingdao Key Laboratory of Biomacromolecular Drug Discovery and Development, College of Chemical Engineering, Qingdao University of Science and Technology, Qingdao 266042, China.
Guozhen DongQingdao Key Laboratory of Biomacromolecular Drug Discovery and Development, College of Chemical Engineering, Qingdao University of Science and Technology, Qingdao 266042, China.
Liyan GongQingdao Key Laboratory of Biomacromolecular Drug Discovery and Development, College of Chemical Engineering, Qingdao University of Science and Technology, Qingdao 266042, China.
Han WuQingdao Center of Technology Innovation for Shark Antibody Development, College of Biological Engineering, Qingdao University of Science and Technology, Qingdao 266042, China.
Chuanliang ZhangQingdao Key Laboratory of Biomacromolecular Drug Discovery and Development, College of Chemical Engineering, Qingdao University of Science and Technology, Qingdao 266042, China.ORCID https://orcid.org/0000-0002-9719-0554
Yuchao GuQingdao Center of Technology Innovation for Shark Antibody Development, College of Biological Engineering, Qingdao University of Science and Technology, Qingdao 266042, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type 2 diabetes mellitus and obesity are closely linked metabolic disorders driven by insulin and leptin resistance. Current long-acting therapies capable of addressing both conditions are dominated by incretin-based agents, which primarily achieve efficacy through appetite suppression and are frequently associated with tolerability limitations and metabolic rebound after treatment discontinuation. Alternative strategies that correct underlying signaling defects without suppressing food intake remain lacking. Protein tyrosine phosphatases PTPN1 and PTPN2 act as coordinated intracellular negative regulators of insulin and leptin signaling by dephosphorylating key molecules within the IRS-AKT and JAK2-STAT3 pathways. Although genetic studies have established these phosphatases as attractive therapeutic targets, translation has been hindered by the absence of long-acting inhibitors with robust

Identifiers

PMID42851992
PMCPMC13647951

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.